5 años luego del estudio Espirit, tratamientos en psoriasis muestran seguridad y efectividad.

No new safety signals were observed with adalimumab treatment during an initial 5-year registry review, according to a study of 6,059 patients with moderate to severe, chronic plaque psoriasis. Researchers found:

• The rate of serious treatment-emergent adverse events per 100 patient-years of adalimumab exposure (E/100PY) was 4.3.

• Rate of serious infection was 1.0 E/100PY.

• Rate of malignancies was 0.9 E/100PY, including nonmelanoma skin cancers, 0.6 E/100PY and melanoma, < 0.1 E/100PY.

• Standardized mortality ratio was 0.3.

• Physician Global Assessment of "clear" or "minimal" was achieved by 57.0% at 12 months and 64.7% at 60 months.

Citation: Menter A, Thaci D, Papp K, et al. Five-year analysis from the ESPRIT 10-year postmarketing surveillance registry of adalimumab treatment for moderate to severe psoriasis. [Published online ahead of print July 16, 2015]. J Am Acad Dermatol. doi: 10.1016/j.jaad.2015.06.038.